This trial will test whether the drug guselkumab is effective in treating giant cell arteritis, in combination with a tapering regimen of glucocorticoids.
- Giant Cell Arteritis
1 Primary · 18 Secondary · Reporting Duration: From Week 28 up to Week 52
Side Effects for
2 Treatment Groups
1 of 2
1 of 2
51 Total Participants · 2 Treatment Groups
Primary Treatment: Guselkumab · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
To what extent have prior experiments featured Guselkumab?
"At the moment, 19 clinical trials are in progress to evaluate Guselkumab's efficacy with 7 of them at a Phase 3 level. While Milan, Kansas is known for its many studies on this medication, over two thousand six hundred and eighty-six sites worldwide have opened research on it." - Anonymous Online Contributor
Is the study being conducted across multiple centers in North America?
"This trial is including patients from Hopital du Sacre-Coeur de Montreal, Mount Sinai Hospital, Massachusetts General Hospital and 4 other clinical sites." - Anonymous Online Contributor
Are there any slots left for enrollment in this research investigation?
"Affirmative. According to clinicaltrials.gov, this medical trial is currently recruiting for 51 participants from 4 separate sites. The study was initated on December 10th 2020 and has been amended as recently as November 3rd 2022." - Anonymous Online Contributor
Has Guselkumab obtained governmental authorization for public use?
"Guselkumab's safety is evaluated with a rating of 2, as it has yet to yield conclusive evidence on its efficacy despite demonstrating some success in regards to patient protection." - Anonymous Online Contributor
What is the current size of the participant pool for this investigation?
"A minimum of 51 qualified subjects are essential for the successful completion of this trial. Janssen Research & Development, LLC is responsible for its management and will be running it out of multiple locations such as Hopital du Sacre-Coeur de Montreal in Quebec and Mount Sinai Hospital in Toronto, Ontario." - Anonymous Online Contributor
Is this trial a pioneering endeavor in its therapeutic field?
"Since 2018, Janssen Research & Development, LLC. has been studying Guselkumab with the first trial involving 1406 participants. After receiving Phase 2 and 3 drug approval due to positive results from this initial research there are now 19 ongoing studies for Guselkumab located in 57 different countries across 282 cities worldwide." - Anonymous Online Contributor